Latest From Seegene Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in November and December 2016.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
Emerging Irish IVD company HiberGene Diagnostics has just CE marked HG Meningococcus, a molecular diagnostic test for bacterial meningitis that can detect Neisseria meningitidis in cerebrospinal fluid, whole blood and via a nasopharyngeal swab in less than one hour. The company is set to launch the test in Europe with distribution agreements in place for Ireland, Germany, Austria, Spain, Turkey and Poland.
The global molecular diagnostics market will grow by $2.4 billion over the next five years according to a global market report from Medtech Insight. Major factors contributing to the healthy growth of this market include advances in technology, as well as the growing understanding of the human genome, pharmacogenomics and the relationship between genes and disease/infection.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Seegene Inc.
- Senior Management
- Jong-Yoon Chun, PhD, Pres. & CEO
- Contact Info
Phone: (82) 2-2240-4000
91, Ogeum-ro, Songpa-gu
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.